154 related articles for article (PubMed ID: 29397195)
1. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis.
Ahuja NK; Mische L; Clarke JO; Wigley FM; McMahan ZH
Semin Arthritis Rheum; 2018 Aug; 48(1):111-116. PubMed ID: 29397195
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal involvement in systemic sclerosis: diagnosis and management.
McMahan ZH; Hummers LK
Curr Opin Rheumatol; 2018 Nov; 30(6):533-540. PubMed ID: 30234725
[TBL] [Abstract][Full Text] [Related]
3. Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.
Manini ML; Camilleri M; Grothe R; Di Lorenzo C
Paediatr Drugs; 2018 Apr; 20(2):173-180. PubMed ID: 29243034
[TBL] [Abstract][Full Text] [Related]
4. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.
Boeckxstaens GE; Bartelsman JF; Lauwers L; Tytgat GN
Am J Gastroenterol; 2002 Jan; 97(1):194-7. PubMed ID: 11811166
[TBL] [Abstract][Full Text] [Related]
5. The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies.
Robinson-Papp J; Nmashie A; Pedowitz E; George MC; Sharma S; Murray J; Benn EKT; Lawrence SA; Machac J; Heiba S; Kim-Schulze S; Navis A; Roland BC; Morgello S
J Neurovirol; 2019 Aug; 25(4):551-559. PubMed ID: 31098925
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine.
O'Dea CJ; Brookes JH; Wattchow DA
Colorectal Dis; 2010 Jun; 12(6):540-8. PubMed ID: 19508545
[TBL] [Abstract][Full Text] [Related]
7. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
[TBL] [Abstract][Full Text] [Related]
8. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience.
Kanjwal K; Karabin B; Sheikh M; Elmer L; Kanjwal Y; Saeed B; Grubb BP
Pacing Clin Electrophysiol; 2011 Jun; 34(6):750-5. PubMed ID: 21410722
[TBL] [Abstract][Full Text] [Related]
9. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).
Sallam H; McNearney TA; Chen JD
Aliment Pharmacol Ther; 2006 Mar; 23(6):691-712. PubMed ID: 16556171
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal manifestations of systemic sclerosis.
Abu-Shakra M; Guillemin F; Lee P
Semin Arthritis Rheum; 1994 Aug; 24(1):29-39. PubMed ID: 7985035
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine.
Pasha SF; Lunsford TN; Lennon VA
Gastroenterology; 2006 Nov; 131(5):1592-6. PubMed ID: 17101331
[TBL] [Abstract][Full Text] [Related]
12. Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis.
Dein EJ; Wigley FM; McMahan ZH
BMC Gastroenterol; 2021 Apr; 21(1):174. PubMed ID: 33858329
[TBL] [Abstract][Full Text] [Related]
13. Pyridostigmine for reversal of severe sequelae from botulinum toxin injection.
Young DL; Halstead LA
J Voice; 2014 Nov; 28(6):830-4. PubMed ID: 25008379
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal manifestations on impaired quality of life in systemic sclerosis.
Yang H; Xu D; Li MT; Yao Y; Jin M; Zeng XF; Qian JM
J Dig Dis; 2019 May; 20(5):256-261. PubMed ID: 30838807
[TBL] [Abstract][Full Text] [Related]
15. Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis.
Omair MA; Lee P
J Rheumatol; 2012 May; 39(5):992-6. PubMed ID: 22467930
[TBL] [Abstract][Full Text] [Related]
16. Focussing on the fundaments - assessing and treating Clozapine Induced Gastrointestinal Hypomotility.
Blackman G; Kapila A; Grosskopf CM; Dratcu L
Int J Psychiatry Clin Pract; 2020 Mar; 24(1):18-19. PubMed ID: 31910056
[No Abstract] [Full Text] [Related]
17. Determining the Risk Factors and Clinical Features Associated With Severe Gastrointestinal Dysmotility in Systemic Sclerosis.
McMahan ZH; Paik JJ; Wigley FM; Hummers LK
Arthritis Care Res (Hoboken); 2018 Sep; 70(9):1385-1392. PubMed ID: 29193842
[TBL] [Abstract][Full Text] [Related]
18. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
Baron M; Hudson M; Steele R; Lo E;
J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
[TBL] [Abstract][Full Text] [Related]
19. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature.
Jaovisidha K; Csuka ME; Almagro UA; Soergel KH
Semin Arthritis Rheum; 2005 Feb; 34(4):689-702. PubMed ID: 15692963
[TBL] [Abstract][Full Text] [Related]
20. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
Khanna D; Furst DE; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Hays RD
J Rheumatol; 2011 Sep; 38(9):1920-4. PubMed ID: 21724699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
